^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TAEK-VAC-HerBy vaccine
i
Other names: TAEK-VAC-HerBy vaccine
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Bavarian Nordic
Drug class:
Immunomodulator
Related drugs:
4d
TAEK-VAC-HerBy-001: TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer (clinicaltrials.gov)
P1, N=55, Active, not recruiting, Bavarian Nordic | Trial completion date: Jun 2026 --> Jan 2025 | Trial primary completion date: Jun 2024 --> Feb 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Perjeta (pertuzumab) • TAEK-VAC-HerBy vaccine
10ms
TAEK-VAC-HerBy-001: TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer (clinicaltrials.gov)
P1, N=55, Active, not recruiting, Bavarian Nordic | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy • Metastases
|
Perjeta (pertuzumab) • TAEK-VAC-HerBy vaccine
over4years
Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients (clinicaltrials.gov)
P1/2, N=45, Recruiting, Bavarian Nordic | Not yet recruiting --> Recruiting
Clinical • Enrollment open • Combination therapy
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 amplification • HER-2 negative • HER-2 expression • ER positive + PGR positive • PGR positive
|
TAEK-VAC-HerBy vaccine
almost5years
Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients (clinicaltrials.gov)
P1/2, N=45, Not yet recruiting, Bavarian Nordic
Clinical • New P1/2 trial • Combination therapy
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 amplification • HER-2 negative • HER-2 expression • ER positive + PGR positive • PGR positive
|
TAEK-VAC-HerBy vaccine
Share via
